Major U.S. Pfizer Brands

U.S. Sales Driven by Massive Price Increases as Rxs Eroded

Other Major U.S. Brands 

Pfizer’s Lyrica (seizures/nerve pain, on U.S. market since 2004)

  • 2005 Reported U.S. Sales: $717 million
  • 2017 Reported U.S. Sales: $3.5 billion
  • 2017 U.S. Sales WITHOUT Price Increases: $1.16 billion
  • Cumulative harm since start of Part D: $10.0+ billion

Other major U.S. Pfizer brands:

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
Something went wrong. Please check your entries and try again.
Scroll to Top